aKen Medical Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
5
aKen Medical General Information
Description
Developer of a modular nanoparticle platform designed to facilitate targeted alpha therapy for solid tumors. The company's platform utilizes proprietary core/shell nanoparticles, metallic containment, and real-time PET mapping to provide image-guided radioligand therapy, predictive dosimetry, and multivalent tumor targeting, enabling healthcare providers to deliver concentrated radiation doses while monitoring accumulation through a unified digital environment.
Contact Information
Website
www.akenmedical.comCorporate Office
- 7 Rue De La Croix Martre
- 91120 Palaiseau
- France
Corporate Office
- 7 Rue De La Croix Martre
- 91120 Palaiseau
- France
aKen Medical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Accelerator/Incubator | 01-Jan-2025 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 20-Nov-2023 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 01-Jul-2023 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Jan-2023 | Completed | Startup | |||
| 1. Accelerator/Incubator | Completed | Startup |
aKen Medical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
aKen Medical Patents
aKen Medical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024394159-A1 | Core/shell radioactive nanoparticles useful in targeted radiotherapy | Pending | 08-Dec-2023 | ||
| AU-2024396724-A1 | Core/shell radioactive nanoparticles useful in targeted radiotherapy | Pending | 08-Dec-2023 | ||
| EP-4820071-A1 | Core/shell radioactive nanoparticles useful in targeted radiotherapy | Pending | 08-Dec-2023 | ||
| EP-4820072-A1 | Core/shell radioactive nanoparticles useful in targeted radiotherapy | Pending | 08-Dec-2023 | ||
| WO-2025120228-A1 | Core/shell radioactive nanoparticles useful in targeted radiotherapy | Inactive | 08-Dec-2023 | A61K51/1244 |
aKen Medical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
aKen Medical Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Boost Invest MedVallée | Accelerator/Incubator | |||
| Paris Biotech Sante | Accelerator/Incubator | |||
| Arion Venture Capital | Family Office | Minority | ||
| La Synapse | Accelerator/Incubator | |||
| PC'up Incubator | Accelerator/Incubator |
aKen Medical FAQs
-
When was aKen Medical founded?
aKen Medical was founded in 2022.
-
Where is aKen Medical headquartered?
aKen Medical is headquartered in Palaiseau, France.
-
What is the size of aKen Medical?
aKen Medical has 6 total employees.
-
What industry is aKen Medical in?
aKen Medical’s primary industry is Other Healthcare Technology Systems.
-
Is aKen Medical a private or public company?
aKen Medical is a Private company.
-
What is aKen Medical’s current revenue?
The current revenue for aKen Medical is .
-
Who are aKen Medical’s investors?
Boost Invest MedVallée, Paris Biotech Sante, Arion Venture Capital, La Synapse, and PC'up Incubator have invested in aKen Medical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
